demonstrated reverse remodeling as defined by a 10% reduction in the LV end systolic volume (ESV). Patients with Ն10% reduction in LV ESV had significantly less 1 year mortality (0% vs. 20%, pϭ0.036) ( Figure) and had: less diabetes, lower baseline LVEF, higher LV ESV and LV end systolic diameter (ESD)posterior wall thickness (PWT), and worst pulmonary vein flow with decreased pulmonary vein S/D velocity (all pϽ0.05), less post TAVR aortic insufficiency (AI) (pϭ0.059), at 6 months of follow-up patients with reverse remodeling were more likely to have more improvement in LV ESV, EDV, LVEF and LV ESD (all pϽ0.05) (Table) . In the binary logistic regression analysis significant predictors of reverse remodeling was the severity of AI after the procedure (OR 9.5, 95% CI 1.3-68, pϭ0.025).
Neocure, Washington, DC Background: As Medicare coverage policies around utilization of new aortic valve technologies are beginning to include procedure utilization requirements for hospital certification, it is increasingly important to know more about the geographic variation of current aortic valve replacement (AVR) procedures. The purpose of this study is to describe the variation in patterns of care and costs associated with AVR procedures in the hospital inpatient setting from a Medicare perspective. Methods: Medicare inpatient hospitalizations for aortic valve replacement (AVR) procedures were identified using ICD-9-CM procedure codes found in the Medicare Provider Analysis and Review (MEDPAR) 2010 database. Hospital volumes, charges, costs, and reimbursements were summarized by hospital, Hospital Referral Region (HRR) and Medicare region. Results: We found a total of 48,449 inpatient AVR procedures completed across 1,147 Medicare participating hospitals in 2010. Total inpatient AVR procedure costs were $2.1 billion, with Medicare reimbursement totaling almost $2.4 billion. Per procedure, the average hospital net Medicare margin was 10.3% or $5,927. The top 5 HRRs with the highest volume of AVR procedures included Manhattan, NY, Los Angeles, CA, Cleveland, OH, Boston, MA and Philadelphia, PA. Medicare Region 4 (Atlanta) and Region 5 (Chicago) represented the highest regional volume of AVR procedures capturing over 36% of market share with Region 8 (Denver) having the lowest AVR procedure volume. Similarly, 36% of AVR procedures were performed at 9.4% of hospitals. Conclusions: AVR procedures are seemingly concentrated in certain parts of the country and at certain hospitals. As Medicare sets volume requirements to allow hospitals to perform certain new AVR procedures, the implications of this variation warrant further analysis.
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Incidence Background: Transcatheter aortic valve replacement (TAVR) involves placement of a stented valve across the native diseased aortic valve. Concern about platelets consumption and acquired thrombocytopenia (AT) was raised in the early TAVR experience. Methods: Between 2008 and 2011, 218 consecutive pts with severe aortic stenosis underwent TAVR using the 23mm or 26mm Edwards SAPIEN valve. Platelet count was evaluated the day prior and daily for 7 days after TAVR. AT was defined as a drop in platelet count of Ͼ50% of baseline. Thirty-day bleeding rate (life threatening or major by VARC criteria) and 1-year mortality was evaluated. Results: Post TAVR platelet count dropped by an average of 78ϩ/Ϫ44 x109/L. Post-TAVR AT was present in 45/218 (20.6%) of subjects. At baseline, the AT group had a higher frequency of female sex, prior coronary intervention, 23mm valve, higher mean gradient and baseline platelet count. Post-op hemoglobin drop (3.3ϩ/Ϫ1.3 vs 2.3ϩ/Ϫ1.1, pϭ0.001) and at least 1 red blood cell transfusion (52.0% vs. 21.5%, pϭ0.001) were more frequent in AT group. Bleeding events occurred in 53.3% (24/45) in AT group vs 29.5% (51/173) in no AT group .9], pϭ0.002. One-year mortality was higher in AT group [32.5% vs.18%, adjusted HR 3.2 (1.5-6.8) pϭ0.002]. 
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